CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
血液系统恶性肿瘤中的 CAR-T 细胞治疗：现状与未来走向
英文原题：CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
查看英文原题
CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T（CAR-T）疗法已成为癌症治疗中革命性的新支柱，尤其是在复发/难治性（r/r）B细胞恶性肿瘤中。随着在血液系统恶性肿瘤中令人瞩目的临床结果，FDA已批准六种CAR-T 细胞产品用于淋巴瘤、白血病和骨髓瘤等适应症。尽管CAR-T 细胞治疗具有诸多优势，但仍存在若干挑战影响其治疗效果。与治疗相关的严重不良反应仍是一个主要问题。此外，治疗药物的持久性差和抗原逃逸常常导致肿瘤复发。高昂的治疗成本进一步成为其有效实施的重大障碍，限制了其可及性。本综述介绍了CAR-T 研究的进展、阻碍血液系统恶性肿瘤患者获得良好结局的关键障碍，以及一些克服这些障碍的策略。
展开英文摘要原文
Chimeric antigen receptor T (CAR-T) therapy has emerged as a revolutionary new pillar in cancer care, particularly in relapsed/refractory (r/r) B-cell malignancies. Following impressive clinical outcomes in hematological malignancies, the FDA-approved six CAR-T cell products for indications such as lymphoma, leukemia, and myeloma. Despite the numerous advantages of CAR-T cell treatment, several challenges exist that interfere with its therapeutic efficacy. Serious adverse effects connected with the treatment continue to be a major concern.
In addition, poor persistence of therapeutics and antigen escape frequently result in tumor relapse. Exorbitant treatment cost further remains a significant barrier to its effective implementation, limiting its accessibility. This review presents progress of CAR-T research, the key obstacles that hamper promising outcomes for patients with hematological malignancies, and a few strategies to overcome them.
论文信息
- 作者
- Khan AN、Asija S、Pendhari J、Purwar R
- 单位
- Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, India.India
- 文献类型
- 综述
- 期刊
- European journal of haematology2024 Jan
- 原文标识
- PubMed 37545253 · DOI 10.1111/ejh.14076